title: Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base.
abstract: Two chelating ligands based on secondary amines have been selected to prepare four new Pt(II) compounds. The ligands bis(pyridine-2-yl)amine, abbreviated dpa, and bis(pyrimidine-2-yl)amine, abbreviated dipm, are chosen to design a rigid chelating motif to allow the study of subtle differences in electronic properties and hydrogen bonding ability. Different carrier ligands (i.e. chloride and ammine) have also been introduced to allow a study of structure-activity relationships. Two of the four compounds are cisplatin analogues, whereas the other two are cationic and coordinatively saturated compounds. The four synthesized and characterized compounds are [Pt(dpa)Cl(2)], [Pt(dpa)(NH(3))(2)](NO(3))(2), [Pt(dipm)Cl(2)] and [Pt(dipm)(NH(3))(2)](NO(3))(2) with code numbers C1-C4. The spatial structures of all these compounds have also been optimized using DFT (density functional theory) calculations. The cytotoxicity of these compounds has been investigated in seven human tumor cell lines using the SRB (sulforhodamine B) assay. The most promising antitumor active compound appears to be C3, [Pt(dipm)Cl(2)]. Two water-soluble compounds, C2 and C4 exhibit selective activity in EVSA-T cell line. In addition, the reaction of the cisplatin analogues with the model base 9-ethylguanine has been followed by proton and platinum NMR spectroscopy.
authors: Leiden Institute of Chemistry, Leiden University, The Netherlands.
authors: Sudeshna
authors: S
authors: Roy
authors: Joyce A
authors: JA
authors: Westmaas
authors: Francesco
authors: F
authors: Buda
authors: Jan
authors: J
authors: Reedijk
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D002247:Carbon Isotopes; D045744:Cell Line, Tumor; D002614:Chelating Agents / Q000378:metabolism*; D002945:Cisplatin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D004355:Drug Stability; D006147:Guanine / Q000031:analogs & derivatives / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D015394:Molecular Structure; D009944:Organoplatinum Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D021241:Spectrometry, Mass, Electrospray Ionization; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D002247:Carbon Isotopes; D002614:Chelating Agents; D008024:Ligands; D009944:Organoplatinum Compounds; C544098:cis-dichlorido(2,20-dipyrimidine-2-ylamine)platinum(II); D006147:Guanine; C014542:9-ethylguanine; D002945:Cisplatin